LRRC4B

Across TCGA pan-cancer cohorts, LRRC4B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LRRC4B data layer compared with 26 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher LRRC4B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LRRC4B expression acts as an unfavorable survival marker.

SARC, ACC, and BLCA are the cancer types where LRRC4B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	OS	Median	All	0.032	0.861	<.001	12	view →
ACC	OS	Median	All	0.188	0.820	<.001	12	view →
BLCA	DFS	Median	III,IV	0.153	0.574	.005	6	view →
ESCA	DFS	Median	All	0.298	0.542	.027	6	view →
SKCM	OS	Median	IV	0.415	0.861	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LRRC4B–SARC (OS)

Open the SARC breakdown →